ARTICLE | Clinical News
MDT-637: Phase I data
May 21, 2012 7:00 AM UTC
The double-blind, placebo-controlled, U.S. Phase I Study MDT-637-CP-101 trial in healthy volunteers showed that single ascending-doses of MDT-637 were well tolerated with no significant adverse events or clinically significant changes in lung function reported. Additionally, MicroDose said MDT-637 was present in the respiratory tract at levels that were several orders of magnitude higher than concentrations necessary to inhibit clinical isolates of RSV in vitro. ...